Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1394&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1395&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7085", "attributes": { "award_id": "3U01HG008657-06S1", "title": "eMERGE SARS-CoV-2 Supplement: Pulmonary, renal, and inflammatory components", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22881, "first_name": "ROBB KENNETH", "last_name": "Rowley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-11", "end_date": "2025-04-30", "award_amount": 375152, "principal_investigator": { "id": 22882, "first_name": "David Russell", "last_name": "Crosslin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22883, "first_name": "Gail Pairitz", "last_name": "Jarvik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "As of May 4, 2020, more than 3.5M cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) and 250,000 deaths have been reported worldwide, with more than 1.2M cases and over 70,000 deaths in the United States. The severity of infection varies from no symptoms to respiratory failure and death. Genetic factors appear to underlie some interindividual variability in SARS-CoV-2 infection outcomes. Part of this heritability may be associated with host immune response, as lymphocyte measures at hospital admission predict disease severity. It may be may also be important to understand whether an individual's underlying or “baseline” lymphocyte count is a risk factor for infection and/or severe disease; a multiancestry polygenic risk score for lymphocytes will be tested for its prediction of COVID-19 severity to address this hypothesis. This supplemental project will improve 1) standardization of electronic health record phenotyping of the pulmonary and renal complications of COVID-19 to improve transferability across sites; and 2) our understanding of host genetic risk factors playing a role in disease severity. We propose to work within the aims of eMERGE4 to study interindividual variability in COVID-19 severity by developing transferable EHR phenotyping of pulmonary and renal outcomes, evaluating ABO blood group association and GWAS contrasting those COVID-19 patients with respiratory failure (inpatient) with those who remained outpatients, and evaluating whether a multi-ancestry PRS for lymphocytes predicts COVID severity. This project can stand on its own, but we will gain power by pooling data across eMERGE and benefit by testing EHR phenotyping at multiple sites to assure transferability. We will also broadly share any data.", "keywords": [ "2019-nCoV", "ABO blood group system", "Abdominal Pain", "Acute", "Acute respiratory failure", "Address", "Administrative Supplement", "Adult", "Adult Respiratory Distress Syndrome", "Affect", "Anosmia", "Basophils", "Blood Cells", "COVID-19", "Cardiovascular system", "Caring", "Case Series", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Chest", "Chronic", "Clinical Trials", "Clinical effectiveness", "Collaborations", "Coughing", "Critical Care", "Critical Illness", "Dangerousness", "Data", "Data Pooling", "Development", "Diagnosis", "Diarrhea", "Disease", "Elderly", "Electronic Health Record", "Evaluation", "Fatigue", "Fever", "Funding", "General Hospitals", "Genetic", "Genetic Predisposition to Disease", "Genetic study", "Genotype", "Headache", "Health", "Hematology", "Heritability", "Hospitalization", "Human", "Image", "Immune response", "Individual", "Infection", "Inflammatory", "Injury to Kidney", "Inpatients", "Institutes", "Intensive Care", "Intensive Care Units", "Interleukin-6", "Kidney", "Leukocytes", "Lung", "Lung diseases", "Lymphocyte", "Lymphocyte Count", "Lymphopenia", "Measures", "Modeling", "Myalgia", "Outcome", "Outpatients", "Participant", "Pathway interactions", "Patients", "Persons", "Phenotype", "Play", "Pneumonia", "Prevention strategy", "Recovery", "Reporting", "Respiratory Failure", "Risk Factors", "Role", "Severities", "Severity of illness", "Shortness of Breath", "Site", "Sore Throat", "Standardization", "Symptoms", "Testing", "Thrombosis", "Time", "Twin Multiple Birth", "United States", "Universities", "Validation", "Variant", "Viral", "Washington", "Work", "clinically relevant", "cohort", "comorbidity", "coronavirus disease", "cytokine", "design", "early childhood", "eosinophil", "genetic analysis", "genetic risk factor", "genome wide association study", "improved", "infancy", "male", "monocyte", "mortality", "myocardial injury", "phenotyping algorithm", "polygenic risk score", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "7090", "attributes": { "award_id": "3U24DA041147-06S1", "title": "ABCD-USA Consortium: Coordinating Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21593, "first_name": "Bethany", "last_name": "Deeds", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-09-30", "end_date": "2027-03-31", "award_amount": 471517, "principal_investigator": { "id": 22887, "first_name": "SANDRA A", "last_name": "BROWN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22888, "first_name": "TERRY L.", "last_name": "JERNIGAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Adolescent Brain Cognitive Development (ABCD) is the largest long-term study of brain development and child health in the United States. ABCD consists of a Coordinating Center, a Data Analysis and Informatics Resource Center, and 21 research sites across the U.S. ABCD has enrolled a diverse sample of 11,878 9-10 year-olds, and is tracking their biological and behavioral development through adolescence into young adulthood. All participants receive repeated state-of-the-art neuroimaging, neuropsychological testing, bioassays, and detailed youth and parent assessments of substance use, mental health, physical health, and culture and environment. In March 2020, when our participants are ages 11-13, the world became substantially affected by the COVID- 19 pandemic, leading to an upheaval in the economy and the lives of almost every family. The majority of U.S. schools closed to reduce viral spread. Many parents incurred changes in work (from home, longer shifts, reduced wages, and/or job loss), some services and support systems became disrupted, and case counts and death tolls surge. The massive multifaceted impact of this unprecedented event has the potential to affect for decades those who are currently children. The proposed research immediately leverages the ABCD cohort, infrastructure, and existing protocol to rapidly characterize the impacts of the COVID-19 pandemic on each child in the study. By collecting this situational information as soon as possible, we can use existing ABCD data to examine perturbations in developmental trajectories of brain functioning, cognition, substance use, academic achievement, social functioning, and physical and mental health. The proposed project would query all ABCD participants and their parents multiple times about the impact of the pandemic on their lives and, in a subset of participants, examine their physical activity and sleep objectively with activity trackers (Fitbits), over the months of school closures, job loss, and disease spread. This will allow the consortium and scientific community at large to test multiple aims regarding how various facets of the pandemic affect development. This includes: (1) characterizing the impact of the COVID-19 pandemic on brain and cognitive development and onset of substance use; (2) evaluating the extent to which alternative schooling approaches exacerbate or mitigate the impact of the pandemic on brain and cognitive development and substance use outcomes; and (3) evaluating the extent to which family stressors exacerbate or mitigate the impact of the pandemic on neurobiological, cognitive, and substance use outcomes. This unprecedented crisis provides an opportunity to make use of ABCD’s elaborate infrastructure and rigorous scientific processes to discern critical dimensions of development not previously envisioned.", "keywords": [ "10 year old", "Academic achievement", "Accelerometer", "Address", "Adolescence", "Adolescent", "Affect", "Age", "Alcohol or Other Drugs use", "Amygdaloid structure", "Anisotropy", "Anterior", "Behavior", "Behavioral", "Biological", "Biological Assay", "Birth", "Brain", "COVID-19 pandemic", "Cessation of life", "Child", "Child Development", "Child Health", "Cognition", "Cognitive", "Communities", "Data", "Data Analyses", "Development", "Dimensions", "Disasters", "Disease", "Economics", "Enrollment", "Environment", "Epigenetic Process", "Event", "Exposure to", "Family", "Fiber", "Food Access", "Genetic", "Health Resources", "Hippocampus (Brain)", "Home environment", "Infrastructure", "Instruction", "Insula of Reil", "Knowledge", "Learning", "Life", "Longitudinal Studies", "Medical", "Memory", "Mental Health", "Moods", "Myelin", "Neurobiology", "Neuropsychological Tests", "Occupations", "Outcome", "Parents", "Participant", "Pathway interactions", "Physical activity", "Procedures", "Process", "Protocols documentation", "Psyche structure", "Research", "Resource Informatics", "Rotation", "Sampling", "Schools", "Services", "Site", "Sleep", "Social Functioning", "Social Interaction", "Stress", "Support System", "Testing", "Thick", "Time", "United States", "United States National Institutes of Health", "Viral", "Wages", "Work", "Youth", "adolescent substance use", "cognitive control", "cognitive development", "cognitive testing", "cohort", "fitbit", "food insecurity", "improved", "meetings", "neuroimaging", "pandemic disease", "physical conditioning", "recruit", "response", "stressor", "support network", "trauma exposure", "tv watching", "virtual", "young adult" ], "approved": true } }, { "type": "Grant", "id": "7091", "attributes": { "award_id": "3U24DA041147-06S5", "title": "ABCD-USA Consortium: Coordinating Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21593, "first_name": "Bethany", "last_name": "Deeds", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-04-16", "end_date": "2021-03-31", "award_amount": 157487, "principal_investigator": { "id": 22887, "first_name": "SANDRA A", "last_name": "BROWN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22888, "first_name": "TERRY L.", "last_name": "JERNIGAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Adolescent Brain Cognitive Development (ABCD) is the largest long-term study of brain development and child health in the US. ABCD consists of a Coordinating Center, a Data Analysis and Informatics Resource Center, and 21 research sites. ABCD has enrolled a diverse sample of 11,878 9-10 year-olds, and is tracking their biological and behavioral development through adolescence into young adulthood. All participants receive repeated detailed youth and parent assessments of physical health, mental health, substance use, and culture and environment, and state-of-the-art neuroimaging, neuropsychological testing, and bioassays. In March 2020, when our participants are ages 11-13, the world became substantially affected by the COVID- 19 pandemic, leading to an upheaval in the economy and the lives of almost every family. The majority of US schools closed to reduce viral spread. Many parents incurred changes in work (from home, longer shifts, reduced wages, and/or job loss), some services and support systems became disrupted, and case counts and death tolls surge. The massive multifaceted impact of this unprecedented event has the potential to affect for decades those who are currently children. The proposed research immediately leverages the ABCD cohort, infrastructure, and existing protocol to rapidly characterize the impacts of the COVID-19 pandemic on each child in the study. By collecting this situational information as soon as possible, we can use existing ABCD data to examine perturbations in developmental trajectories of physical health, mental health, substance use, brain functioning, cognition, academic achievement, and social functioning. The proposed project would query all ABCD participants and their parents multiple times about the impact of the pandemic on their lives and, in a subset of participants, examine their physical activity and sleep objectively with activity trackers (Fitbits), over the months of school closures, job loss, and disease spread. This will allow the consortium and scientific community at large to test multiple aims regarding how various facets of the pandemic affect development and outcomes. This includes: (1) characterizing how the COVID-19 pandemic and social distancing efforts impact physical activity, sedentary behavior, screen media use, and sleep; (2) leveraging sensors to objectively evaluate change in physical activity and sleep as youth transition from pre- pandemic to stay-at-home lifestyles; and (3) evaluating the extent to which changes in health behaviors during the stay-at-home period influence long-term health outcomes in youth. This unprecedented crisis provides an opportunity to make use of ABCD’s elaborate infrastructure and rigorous scientific processes to discern critical dimensions of development not previously envisioned.", "keywords": [ "10 year old", "Academic achievement", "Accelerometer", "Address", "Adherence", "Adolescence", "Adolescent", "Adult", "Affect", "Age", "Alcohol or Other Drugs use", "Area", "Asthma", "Behavior", "Behavioral", "Biological", "Biological Assay", "Birth", "Blood Pressure", "Brain", "COVID-19", "COVID-19 pandemic", "Caring", "Cessation of life", "Child", "Child Health", "Cholesterol", "Cognition", "Communities", "Coronavirus", "Data", "Data Analyses", "Data Collection", "Developed Countries", "Development", "Diabetes Mellitus", "Dimensions", "Disease", "Distance Learning", "Drug usage", "Economics", "Emergency Situation", "Enrollment", "Environment", "Epidemiology", "Event", "Exposure to", "Family", "Family Relationship", "Ferritin", "Future", "Genetic", "Glycosylated hemoglobin A", "Guidelines", "Health", "Health Status", "Health behavior", "Heart Rate", "High Density Lipoprotein Cholesterol", "Home environment", "Hypertension", "Individual Differences", "Infrastructure", "Institution", "Life", "Life Style", "Longitudinal Studies", "Marijuana", "Measures", "Medical", "Mental Health", "National Institute of Mental Health", "Nature", "Neuropsychological Tests", "Obesity", "Occupations", "Outcome", "Parents", "Participant", "Patient Self-Report", "Physical Fitness", "Physical activity", "Physical assessment", "Process", "Protocols documentation", "Public Health", "Questionnaires", "Research", "Research Personnel", "Resource Informatics", "Respiratory Signs and Symptoms", "Respiratory physiology", "Rest", "Sampling", "School-Age Population", "Schools", "Self Administration", "Self Assessment", "Serum", "Services", "Severities", "Site", "Sleep", "Social Distance", "Social Functioning", "Stress", "Supervision", "Support System", "Symptoms", "Testing", "Time", "Tobacco use", "Trauma", "United States", "United States National Institutes of Health", "Update", "Viral", "Virus", "Wages", "Work", "Youth", "alcohol and other drug", "base", "cognitive development", "cognitive testing", "cohort", "data archive", "data sharing", "design", "experience", "fitbit", "food insecurity", "interest", "multimodality", "neuroimaging", "nutrition", "pandemic disease", "physical conditioning", "protocol development", "recruit", "respiratory health", "sedentary lifestyle", "sensor", "social", "stressor", "tv watching", "vaping", "young adult" ], "approved": true } }, { "type": "Grant", "id": "7093", "attributes": { "award_id": "3R01AG066749-01S1", "title": "Finding Combinatorial Drug Repositioning Therapy For Alzheimer'S Disease And Related Dementias", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21472, "first_name": "Jean", "last_name": "Yuan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-04-01", "end_date": "2025-03-31", "award_amount": 389580, "principal_investigator": { "id": 1540, "first_name": "Xiaoqian", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 480, "ror": "https://ror.org/03gds6c39", "name": "The University of Texas Health Science Center at Houston", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22889, "first_name": "Cui", "last_name": "Tao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22890, "first_name": "WENJIN Jim", "last_name": "ZHENG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "AD/ADRD are highly complex diseases characterized by distinct molecular pathways and neuropathological phenotypes. Unfortunately, the treatment remains at best modestly effective and no new drugs have been approved since 2003. Combinatorial drug therapy for AD/ADRD treatment has not been intensively studied but it is highly promising. We hypothesize that finding repositioned drug combinations through innovative exploration of big data may uncover effective AD/ADRD treatments, with implicit advantages in overcoming drug resistance and targeting multiple biomarkers. We will combine big biomedical data from complementary sources, novel and advanced informatics models, clinical domain expertise, as well as biology knowledge and validation into a coherent framework to tackle AD/ADRD with potential combinatorial drug therapies. In an exponentially larger and more challenging space of combinatorial drug therapy, opportunities are also exponentially larger when compared with traditional single-drug models but many computational challenges need to be carefully handled. We will develop multiple computational models under two philosophical umbrellas, with focuses on quantifiable screening and biological understanding. Our findings will be validated with biological experiments from cell to mouse. If successful, we will significantly advance AD/ADRD research and benefit patients with safe and effective treatment.", "keywords": [ "2019-nCoV", "Address", "Administrative Supplement", "Adult", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Alzheimer&apos", "s disease therapy", "Antiviral Agents", "Automobile Driving", "Big Data", "Biological", "Biological Markers", "Biology", "Blood - brain barrier anatomy", "COVID-19", "Cells", "Classification", "Clinical", "Combination Drug Therapy", "Complex", "Computer Models", "Coronavirus", "Custom", "Data", "Databases", "Development", "Disease", "Drug Combinations", "Drug Modelings", "Drug Targeting", "Drug resistance", "Elderly", "Engineering", "Exposure to", "Functional disorder", "Goals", "Healthcare", "Hour", "Human", "Informatics", "Information Retrieval", "Investigation", "Knowledge", "Literature", "Machine Learning", "Manuals", "Mediating", "Metadata", "Methods", "Middle East Respiratory Syndrome", "Mining", "Modeling", "Molecular", "Mus", "Natural Language Processing", "Nature", "Ontology", "Paper", "Parents", "Pathway interactions", "Patients", "Performance", "Pharmaceutical Preparations", "Pharmacogenomics", "Pharmacotherapy", "Phenotype", "Prevention", "Protective Agents", "Protocols documentation", "PubMed", "Publications", "Publishing", "Research", "Research Personnel", "Rest", "Seeds", "Services", "Severe Acute Respiratory Syndrome", "Source", "Surveys", "System", "Update", "Validation", "Viral", "Virus", "base", "big biomedical data", "clinical practice", "combat", "combinatorial", "data mining", "drug candidate", "effective therapy", "experimental study", "human-in-the-loop", "improved", "information model", "innovation", "insight", "knowledge base", "machine learning algorithm", "novel", "novel drug combination", "novel therapeutics", "prevent", "relating to nervous system", "research study", "screening", "software development", "text searching", "tool", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "10262", "attributes": { "award_id": "1U24AI171008-01", "title": "VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebase", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 12912, "first_name": "Misrak", "last_name": "Gezmu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-19", "end_date": "2027-05-31", "award_amount": 753786, "principal_investigator": { "id": 26210, "first_name": "Yongqun", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22889, "first_name": "Cui", "last_name": "Tao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26211, "first_name": "Junguk", "last_name": "Hur", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: Vaccination is one of the most successful innovations in the fight against infectious disease. However, we still lack effective and safe vaccines against many major infectious diseases (e.g., HIV, tuberculosis, and malaria). We also lack a comprehensive and interoperable vaccine knowledgebase to accelerate vaccine development and better understand vaccine safety. Based on the preliminary version of our current VIOLIN vaccine knowledgebase, we propose to develop VIOLIN 2.0, a new generation Vaccine Information and Ontology LInked kNowledgebase. Strong preliminary data were generated: Originally funded by an NIH-NIAID R01, our VIOLIN has grown to include information on >4,000 vaccines for >200 pathogens. In addition, we have led the development of the community-based Vaccine Ontology (VO) and Ontology of Adverse Events (OAE) for vaccine and adverse event representation. We have also developed the widely used Vaxign and Vaxign-ML vaccine design programs and applied them to predict vaccines for many diseases including COVID-19. Many ontology- and bioinformatics-based methods and tools, including natural language processing (NLP) tools, have also been developed to analyze vaccine information and identify new scientific insights. However, the existing VIOLIN also faces new challenges in areas such as knowledge integration, interoperability, and analysis. In this proposal, we aim to systematically develop VIOLIN 2.0, which will be a community-based comprehensive vaccine knowledgebase (KB) with data FAIRness. Basic science, clinical, and public health (safety, epidemiology, vaccine coverage) knowledge will be included with robust linkage and analysis. Four specific aims are proposed: Aim 1: Implement a pipeline for automatic knowledge harvest, standardization, and integration using advanced ontology and natural language processing technologies. Aim 2: Expand the vaccine KB and management. Three specific knowledge aspects will be included: (i) vaccine formulation and development, (ii) protective responses, and (iii) vaccine safety. Aim 3: Provide VIOLIN 2.0 knowledge browser, query, and showcases. For showcase demonstration, three use cases will be built up, including pattern detection of vaccine components (including protective antigens and vaccine adjuvants), vaccine-induced host immune signatures, and vaccine adverse events. The patterns identified will be utilized with statistical and machine learning methods to support rational vaccine design and immune signature prediction. Aim 4: Community engagement and outreach. Many events such as hackathons and workshops will be held to support the development and applications of community-based ontologies, standards, and tools. VIOLIN 2.0 will significantly enhance the VIOLIN with breadth and depth of vaccine information, include knowledge not available in the current VIOLIN (e.g., vaccine adverse events), and develop new methods for efficient and scalable knowledge extraction and analysis. Our study will advance the understanding of vaccine mechanisms, and support rational vaccine design against COVID-19 and other infectious diseases.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Address", "Adjuvant", "Adverse event", "Antigens", "Applications Grants", "Area", "Basic Science", "Bioinformatics", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Clinical", "Clinical Trials", "Communicable Diseases", "Communities", "Community Developments", "Community Outreach", "Consensus", "Data", "Databases", "Detection", "Development", "Dimensions", "Disease", "Educational workshop", "Ensure", "Epidemiology", "Evaluation", "Event", "FAIR principles", "Face", "Funding", "Generations", "Grant", "HIV/TB", "Harvest", "Immune", "Immune response", "Immunologic Factors", "Informatics", "Information Retrieval", "Knowledge", "Knowledge Discovery", "Knowledge Extraction", "Life Cycle Stages", "Link", "Literature", "Machine Learning", "Malaria", "Manuals", "Methods", "Modern Medicine", "Molecular", "Monitor", "National Institute of Allergy and Infectious Disease", "Natural Language Processing", "Ontology", "Pattern", "Public Health", "Reproducibility", "Research", "Resources", "Safety", "Semantics", "Source", "Standardization", "System", "Systems Analysis", "Technology", "United States National Institutes of Health", "Vaccination", "Vaccine Adjuvant", "Vaccine Antigen", "Vaccine Design", "Vaccines", "Visualization", "Work", "base", "community engagement", "data access", "data integration", "disability", "experience", "fight against", "gene expression database", "genetic linkage analysis", "hackathon", "informatics tool", "innovation", "insight", "interoperability", "invention", "knowledge graph", "knowledge integration", "knowledgebase", "machine learning method", "meetings", "method development", "outreach", "pathogen", "programs", "research and development", "response", "statistical and machine learning", "text searching", "tool", "vaccine adverse event", "vaccine development", "vaccine formulation", "vaccine safety", "vector", "web interface", "web site" ], "approved": true } }, { "type": "Grant", "id": "11485", "attributes": { "award_id": "5U24AI171008-02", "title": "VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebase", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 12912, "first_name": "Misrak", "last_name": "Gezmu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-19", "end_date": "2027-05-31", "award_amount": 743543, "principal_investigator": { "id": 26210, "first_name": "Yongqun", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22889, "first_name": "Cui", "last_name": "Tao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26211, "first_name": "Junguk", "last_name": "Hur", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: Vaccination is one of the most successful innovations in the fight against infectious disease. However, we still lack effective and safe vaccines against many major infectious diseases (e.g., HIV, tuberculosis, and malaria). We also lack a comprehensive and interoperable vaccine knowledgebase to accelerate vaccine development and better understand vaccine safety. Based on the preliminary version of our current VIOLIN vaccine knowledgebase, we propose to develop VIOLIN 2.0, a new generation Vaccine Information and Ontology LInked kNowledgebase. Strong preliminary data were generated: Originally funded by an NIH-NIAID R01, our VIOLIN has grown to include information on >4,000 vaccines for >200 pathogens. In addition, we have led the development of the community-based Vaccine Ontology (VO) and Ontology of Adverse Events (OAE) for vaccine and adverse event representation. We have also developed the widely used Vaxign and Vaxign-ML vaccine design programs and applied them to predict vaccines for many diseases including COVID-19. Many ontology- and bioinformatics-based methods and tools, including natural language processing (NLP) tools, have also been developed to analyze vaccine information and identify new scientific insights. However, the existing VIOLIN also faces new challenges in areas such as knowledge integration, interoperability, and analysis. In this proposal, we aim to systematically develop VIOLIN 2.0, which will be a community-based comprehensive vaccine knowledgebase (KB) with data FAIRness. Basic science, clinical, and public health (safety, epidemiology, vaccine coverage) knowledge will be included with robust linkage and analysis. Four specific aims are proposed: Aim 1: Implement a pipeline for automatic knowledge harvest, standardization, and integration using advanced ontology and natural language processing technologies. Aim 2: Expand the vaccine KB and management. Three specific knowledge aspects will be included: (i) vaccine formulation and development, (ii) protective responses, and (iii) vaccine safety. Aim 3: Provide VIOLIN 2.0 knowledge browser, query, and showcases. For showcase demonstration, three use cases will be built up, including pattern detection of vaccine components (including protective antigens and vaccine adjuvants), vaccine-induced host immune signatures, and vaccine adverse events. The patterns identified will be utilized with statistical and machine learning methods to support rational vaccine design and immune signature prediction. Aim 4: Community engagement and outreach. Many events such as hackathons and workshops will be held to support the development and applications of community-based ontologies, standards, and tools. VIOLIN 2.0 will significantly enhance the VIOLIN with breadth and depth of vaccine information, include knowledge not available in the current VIOLIN (e.g., vaccine adverse events), and develop new methods for efficient and scalable knowledge extraction and analysis. Our study will advance the understanding of vaccine mechanisms, and support rational vaccine design against COVID-19 and other infectious diseases.", "keywords": [ "Acceleration", "Acquired Immunodeficiency Syndrome", "Address", "Adjuvant", "Adverse event", "Antigens", "Applications Grants", "Area", "Basic Science", "Bioinformatics", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Clinical", "Clinical Trials", "Collaborations", "Communicable Diseases", "Communities", "Community Developments", "Community Outreach", "Consensus", "Data", "Databases", "Detection", "Development", "Dimensions", "Disease", "Educational workshop", "Ensure", "Epidemiology", "Evaluation", "Event", "FAIR principles", "Face", "Funding", "Generations", "Grant", "HIV", "Harvest", "Immune", "Immune response", "Immunologic Factors", "Informatics", "Information Retrieval", "Knowledge", "Knowledge Discovery", "Knowledge Extraction", "Licensing", "Life Cycle Stages", "Link", "Literature", "Machine Learning", "Malaria", "Manuals", "Methods", "Modern Medicine", "Molecular", "Monitor", "National Institute of Allergy and Infectious Disease", "Natural Language Processing", "Ontology", "Pattern", "Public Health", "Reproducibility", "Research", "Resources", "Safety", "Semantics", "Source", "Standardization", "System", "Systems Analysis", "Technology", "Tuberculosis", "United States National Institutes of Health", "Vaccination", "Vaccine Adjuvant", "Vaccine Antigen", "Vaccine Design", "Vaccines", "Visualization", "Work", "community engagement", "data access", "data integration", "disability", "experience", "fighting", "gene expression database", "hackathon", "improved", "informatics tool", "innovation", "insight", "interoperability", "invention", "knowledge graph", "knowledge integration", "knowledgebase", "machine learning method", "meetings", "method development", "outreach", "pathogen", "predictive signature", "programs", "research and development", "response", "statistical and machine learning", "text searching", "tool", "vaccine adverse event", "vaccine development", "vaccine formulation", "vaccine safety", "vector", "web interface", "web site" ], "approved": true } }, { "type": "Grant", "id": "7093", "attributes": { "award_id": "3R01AG066749-01S1", "title": "Finding Combinatorial Drug Repositioning Therapy For Alzheimer'S Disease And Related Dementias", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21472, "first_name": "Jean", "last_name": "Yuan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-04-01", "end_date": "2025-03-31", "award_amount": 389580, "principal_investigator": { "id": 1540, "first_name": "Xiaoqian", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 480, "ror": "https://ror.org/03gds6c39", "name": "The University of Texas Health Science Center at Houston", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22889, "first_name": "Cui", "last_name": "Tao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22890, "first_name": "WENJIN Jim", "last_name": "ZHENG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "AD/ADRD are highly complex diseases characterized by distinct molecular pathways and neuropathological phenotypes. Unfortunately, the treatment remains at best modestly effective and no new drugs have been approved since 2003. Combinatorial drug therapy for AD/ADRD treatment has not been intensively studied but it is highly promising. We hypothesize that finding repositioned drug combinations through innovative exploration of big data may uncover effective AD/ADRD treatments, with implicit advantages in overcoming drug resistance and targeting multiple biomarkers. We will combine big biomedical data from complementary sources, novel and advanced informatics models, clinical domain expertise, as well as biology knowledge and validation into a coherent framework to tackle AD/ADRD with potential combinatorial drug therapies. In an exponentially larger and more challenging space of combinatorial drug therapy, opportunities are also exponentially larger when compared with traditional single-drug models but many computational challenges need to be carefully handled. We will develop multiple computational models under two philosophical umbrellas, with focuses on quantifiable screening and biological understanding. Our findings will be validated with biological experiments from cell to mouse. If successful, we will significantly advance AD/ADRD research and benefit patients with safe and effective treatment.", "keywords": [ "2019-nCoV", "Address", "Administrative Supplement", "Adult", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Alzheimer&apos", "s disease therapy", "Antiviral Agents", "Automobile Driving", "Big Data", "Biological", "Biological Markers", "Biology", "Blood - brain barrier anatomy", "COVID-19", "Cells", "Classification", "Clinical", "Combination Drug Therapy", "Complex", "Computer Models", "Coronavirus", "Custom", "Data", "Databases", "Development", "Disease", "Drug Combinations", "Drug Modelings", "Drug Targeting", "Drug resistance", "Elderly", "Engineering", "Exposure to", "Functional disorder", "Goals", "Healthcare", "Hour", "Human", "Informatics", "Information Retrieval", "Investigation", "Knowledge", "Literature", "Machine Learning", "Manuals", "Mediating", "Metadata", "Methods", "Middle East Respiratory Syndrome", "Mining", "Modeling", "Molecular", "Mus", "Natural Language Processing", "Nature", "Ontology", "Paper", "Parents", "Pathway interactions", "Patients", "Performance", "Pharmaceutical Preparations", "Pharmacogenomics", "Pharmacotherapy", "Phenotype", "Prevention", "Protective Agents", "Protocols documentation", "PubMed", "Publications", "Publishing", "Research", "Research Personnel", "Rest", "Seeds", "Services", "Severe Acute Respiratory Syndrome", "Source", "Surveys", "System", "Update", "Validation", "Viral", "Virus", "base", "big biomedical data", "clinical practice", "combat", "combinatorial", "data mining", "drug candidate", "effective therapy", "experimental study", "human-in-the-loop", "improved", "information model", "innovation", "insight", "knowledge base", "machine learning algorithm", "novel", "novel drug combination", "novel therapeutics", "prevent", "relating to nervous system", "research study", "screening", "software development", "text searching", "tool", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "7095", "attributes": { "award_id": "3P01AI089473-07S1", "title": "Human Epidemiology and Response to SARS-CoV-2 (HEROS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 9207, "first_name": "Michael", "last_name": "Minnicozzi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-18", "end_date": "2021-08-31", "award_amount": 65682, "principal_investigator": { "id": 22893, "first_name": "Christine C C", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1545, "ror": "https://ror.org/02kwnkm68", "name": "Henry Ford Health System", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22894, "first_name": "Dennis R", "last_name": "Ownby", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1545, "ror": "https://ror.org/02kwnkm68", "name": "Henry Ford Health System", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This request is in response to NOT-AI-20-031 for supplement funding in response to the CoVID19 emergency. COVID-19, the infectious disease caused by SARS-CoV-2, is rapidly affecting humans around the globe. While initial epidemiological data have focused on cases that resulted in severe respiratory disease seen predominantly in adults, little information regarding the infection burden in children is available. This is complicated by the observation that many virologically-confirmed cases in children are asymptomatic. Undocumented, and likely infectious, cases could result in exposure to a far greater proportion of the community than would otherwise occur. Indeed, it has been proposed that undocumented (or silent) infections are the source for almost 80% of documented infections; thus, it is critical to determine the silent and symptomatic infection rate in children. To overcome challenges for clinical study implementation imposed by current healthcare access restrictions, a surveillance study under design will enroll and prospectively observe eligible children, and their family members, that are current participants in our NIH-funded, ongoing, birth cohort studies. These children and their families are known to research staff and as part of their participation in HFHS studies, they have already been exposed to the procedures involved in a surveillance study. We are requesting support for the pediatric studies aligned with our Microbiota and Allergic Asthma Precision Prevention (MAAP2) (PI: Johnson, Ownby P01AI089473) to participate in the multi-center survey entitled Human Epidemiology and Response to SARS-CoV-2 (HEROS), Protocol # DAIT-COVID-19-001. Our primary objective is to report the incidence of SARS-CoV-2 infection (detection of virus in nasal secretions) over time in cohort children (index child) and household contacts (caregivers and siblings). A secondary objective is to compare SARS-CoV-2 infection status and antibody development for index children/siblings with atopic conditions (e.g. asthma, eczema) versus children without atopic conditions. As an exploratory aim, we will investigate whether SARS-CoV-2 infection (as determined by virus detected in nasal secretions) is associated with the presence of virus in stool. Our targeted enrollment is 300 families recruited over a 2-week period and followed for a minimum of 6 months. At predetermined intervals, biological samples (nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. Symptom and exposure surveys will be completed remotely via a smart phone, on-line, or telephone at the time of biological sample collection. This timely, multi-site study can be rapidly implemented and realistically conducted without necessitating any visits to a clinical research center and will provide invaluable information on the infection burden of SARS-CoV-2 in children.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Antibodies", "Asthma", "Biological", "Birth", "COVID-19", "Caregivers", "Cellular Phone", "Child", "Childhood", "Clinical Research", "Cohort Studies", "Communicable Diseases", "Communities", "Development", "Eczema", "Emergency Situation", "Enrollment", "Epidemiology", "Exposure to", "Extrinsic asthma", "Family", "Family member", "Feces", "Funding", "Home environment", "Household", "Human", "Incidence", "Infection", "Lung diseases", "Nose", "Participant", "Procedures", "Protocols documentation", "Reporting", "Research", "Sampling", "Siblings", "Site", "Source", "Surveys", "Swab", "Symptoms", "Telephone", "Time", "United States National Institutes of Health", "Virus", "Visit", "access restrictions", "cohort", "design", "epidemiologic data", "health care availability", "indexing", "individualized prevention", "infection burden", "infection rate", "microbiota", "peripheral blood", "prospective", "recruit", "response", "sample collection", "surveillance study", "viral detection", "virology" ], "approved": true } }, { "type": "Grant", "id": "7096", "attributes": { "award_id": "3P01AI089473-06S1", "title": "Human Epidemiology and Response to SARS-CoV-2 (HEROS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 9207, "first_name": "Michael", "last_name": "Minnicozzi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-18", "end_date": "2021-08-31", "award_amount": 134318, "principal_investigator": { "id": 22893, "first_name": "Christine C C", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1545, "ror": "https://ror.org/02kwnkm68", "name": "Henry Ford Health System", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22894, "first_name": "Dennis R", "last_name": "Ownby", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1545, "ror": "https://ror.org/02kwnkm68", "name": "Henry Ford Health System", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This request is in response to NOT-AI-20-031 for supplement funding in response to the CoVID- 19 emergency. COVID-19, the infectious disease caused by SARS-CoV-2, is rapidly affecting humans around the globe. While initial epidemiological data have focused on cases that resulted in severe respiratory disease seen predominantly in adults, little information regarding the infection burden in children is available. This is complicated by the observation that many virologically-confirmed cases in children are asymptomatic. Undocumented, and likely infectious, cases could result in exposure to a far greater proportion of the community than would otherwise occur. Indeed, it has been proposed that undocumented (or silent) infections are the source for almost 80% of documented infections; thus, it is critical to determine the silent and symptomatic infection rate in children. To overcome challenges for clinical study implementation imposed by current healthcare access restrictions, a surveillance study under design will enroll and prospectively observe eligible children, and their family members, that are current participants in our NIH-funded, ongoing, birth cohort studies. These children and their families are known to research staff and as part of their participation in HFHS studies, they have already been exposed to the procedures involved in a surveillance study. We are requesting support for the pediatric studies aligned with our Microbiota and Allergic Asthma Precision Prevention (MAAP2) (PI: Johnson, Ownby P01AI089473) to participate in the multi-center survey entitled Human Epidemiology and Response to SARS-CoV-2 (HEROS), Protocol # DAIT-COVID-19-001. Our primary objective is to report the incidence of SARS-CoV-2 infection (detection of virus in nasal secretions) over time in cohort children (index child) and household contacts (caregivers and siblings). A secondary objective is to compare SARS-CoV-2 infection status and antibody development for index children/siblings with atopic conditions (e.g. asthma, eczema) versus children without atopic conditions. As an exploratory aim, we will investigate whether SARS-CoV-2 infection (as determined by virus detected in nasal secretions) is associated with the presence of virus in stool. Our targeted enrollment is 300 families recruited over a 2-week period and followed for a minimum of 6 months. At predetermined intervals, biological samples (nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. Symptom and exposure surveys will be completed remotely via a smart phone, on-line, or telephone at the time of biological sample collection. This timely, multi-site study can be rapidly implemented and realistically conducted without necessitating any visits to a clinical research center and will provide invaluable information on the infection burden of SARS-CoV-2 in children.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Antibodies", "Asthma", "Biological", "Birth", "COVID-19", "Caregivers", "Cellular Phone", "Child", "Childhood", "Clinical Research", "Cohort Studies", "Communicable Diseases", "Communities", "Development", "Eczema", "Emergency Situation", "Enrollment", "Epidemiology", "Exposure to", "Extrinsic asthma", "Family", "Family member", "Feces", "Funding", "Home environment", "Household", "Human", "Incidence", "Infection", "Lung diseases", "Nose", "Participant", "Procedures", "Protocols documentation", "Reporting", "Research", "Sampling", "Siblings", "Site", "Source", "Surveys", "Swab", "Symptoms", "Telephone", "Time", "United States National Institutes of Health", "Virus", "Visit", "access restrictions", "cohort", "design", "epidemiologic data", "health care availability", "indexing", "individualized prevention", "infection burden", "infection rate", "microbiota", "peripheral blood", "prospective", "recruit", "response", "sample collection", "surveillance study", "viral detection", "virology" ], "approved": true } }, { "type": "Grant", "id": "7098", "attributes": { "award_id": "3UL1TR003015-02S5", "title": "Convalescent Immune Plasma for the Treatment of COVID-19: Mechanisms Underlying the Host Immunologic and Virologic Response", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 10397, "first_name": "LEONIE", "last_name": "Misquitta", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2021-07-31", "award_amount": 483575, "principal_investigator": { "id": 22896, "first_name": "Donald E", "last_name": "Brown", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 908, "ror": "https://ror.org/0153tk833", "name": "University of Virginia", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22897, "first_name": "KAREN C.", "last_name": "JOHNSTON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 908, "ror": "https://ror.org/0153tk833", "name": "University of Virginia", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global event which has required rapid adaptation to changing clinical and epidemiological circumstances. There are currently limited treatment options available for COVID-19, with an estimated fatality rate of around 4% globally, and as high as 20-50% among hospitalized populations. Convalescent immune plasma (CIP) is a promising potential treatment for a wide range of infectious diseases, and one which can be mobilized rapidly even within the confines of resource limitations in the pandemic setting. Prior studies in other viral pandemics and early evidence from COVID-19 suggests that it may be effective, but formal prospective studies of CIP in COVID-19 are lacking. This project is a multidisciplinary collaborative effort from infectious disease (Dr. Tania Thomas, MD, MPH), pulmonary and critical care (Dr. Jeffrey Sturek, MD, PhD), and cell therapy (Dr. Lawrence Lum, MD, DSc): a phase 2 clinical trial evaluating the efficacy of CIP in COVID- 19 infection. The epidemiology in this largely rural catchment area projects continued enrollment through 2020- 2021 fueled by subpopulations with rapid upswing in incidence, particularly in the latinx community (one of our special populations for clinical research) where our health system has focused outreach and support. The central hypothesis of this proposal is that early infusion of CIP with high titer anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19 respiratory disease will prevent progression to critical illness and death through modulation of the anti-SARS-CoV-2 host immune response. This will be tested through three specific aims: Aim 1) Test the effect of high titer CIP on progression to critical illness and death in moderately ill hospitalized patients with COVID-19 respiratory disease; Aim 2) Determine the effects of CIP on the host immune response. Blood will be collected at 0 (prior to CIP infusion), 7, 14, and 28 days after CIP infusion. A comprehensive immunologic assessment will be performed, including high-dimensional immunophenotyping by mass cytometry, single-cell RNA sequencing, as well as functional in vitro secretion assays. These will be compared to un-treated controls. Statistical modeling will be used to test associations with clinical outcome; Aim 3) Utilize subgenomic messenger RNA analysis to map the course of virologic clearance in COVID-19 disease. Subjects will be tested for viral clearance by serial nasal swab to inform duration of viral viability and implementation of social isolation practices critical for return to settings where distancing/isolation are limited. Completion of this study will help answer a critical question about the effect of CIP on critical illness and death in COVID-19. Importantly the in-depth follow on immunologic and virologic studies will lead to a better understanding of the mechanisms of progression to critical illness with the potential for targeted immune- mediated therapeutics and a diagnostic assay for viral viability that could immediately inform clinical care.", "keywords": [ "2019-nCoV", "Antibodies", "Area", "Biological Assay", "Blood", "COVID-19", "COVID-19 pandemic", "Catchment Area", "Cell Therapy", "Cessation of life", "Clinical", "Clinical Research", "Clinical Trials", "Collaborations", "Communicable Diseases", "Communities", "Critical Care", "Critical Illness", "Cytometry", "Data", "Disease", "Disease Outbreaks", "Doctor of Philosophy", "Ebola", "Enrollment", "Epidemiology", "Event", "Fatality rate", "Health system", "Immune Plasma", "Immune Targeting", "Immune response", "Immunity", "Immunologics", "Immunophenotyping", "In Vitro", "Incidence", "Infection", "Infusion procedures", "Lung", "Lung diseases", "Maps", "Mediating", "Messenger RNA", "Nose", "Odds Ratio", "Outcome", "Outpatients", "Patients", "Pharmacology", "Phase II Clinical Trials", "Plasma", "Population", "Population Density", "Probability", "Procedures", "Prospective Studies", "RNA analysis", "Resources", "Retrospective Studies", "Rural", "Safety", "Social isolation", "Statistical Models", "Swab", "Testing", "Therapeutic", "Universities", "Viral", "Virginia", "Virus Diseases", "Vulnerable Populations", "clinical care", "design", "diagnostic assay", "high dimensionality", "improved", "multidisciplinary", "named group", "neutralizing antibody", "outreach", "pandemic disease", "pathogen", "prevent", "response", "single-cell RNA sequencing", "therapy design", "transfusion medicine", "virology" ], "approved": true } } ], "meta": { "pagination": { "page": 1394, "pages": 1424, "count": 14236 } } }